Cargando…

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma

Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamachi, Naoki, Shimose, Shigeo, Hirota, Keisuke, Koya, Shunji, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Hashida, Ryuki, Kawaguchi, Takumi, Matuse, Hiroo, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947949/ https://www.ncbi.nlm.nih.gov/pubmed/33758660 http://dx.doi.org/10.3892/mco.2021.2241

Ejemplares similares

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis
por: Nakano, Masahito, et al.
Publicado: (2020)

Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound
por: Kamachi, Naoki, et al.
Publicado: (2021)

Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma
por: Okamura, Shusuke, et al.
Publicado: (2022)

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis
por: Shirono, Tomotake, et al.
Publicado: (2021)

Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion
por: Niizeki, Takashi, et al.
Publicado: (2021)

Usefulness of a novel transarterial chemoinfusion plus external‐beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study
por: Shirono, Tomotake, et al.
Publicado: (2021)

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Durable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinoma
por: Shirono, Tomotake, et al.
Publicado: (2022)

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2021)

Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching
por: Shimose, Shigeo, et al.
Publicado: (2023)

Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
por: Suzuki, Hiroyuki, et al.
Publicado: (2022)

Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2016)

Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
por: Shimose, Shigeo, et al.
Publicado: (2020)

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
por: Shimose, Shigeo, et al.
Publicado: (2020)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
por: Iwamoto, Hideki, et al.
Publicado: (2023)

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
por: Nakano, Masahito, et al.
Publicado: (2015)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma
por: Kawaguchi, Takumi, et al.
Publicado: (2020)

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2022)

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer
por: Kuromatsu, Ryoko, et al.
Publicado: (2022)

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2022)

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
por: Iwamoto, Hideki, et al.
Publicado: (2020)

Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma
por: Nakano, M., et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
por: Zaizen, Yuki, et al.
Publicado: (2021)

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study
por: Shimose, Shigeo, et al.
Publicado: (2021)

Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma
por: Hashida, Ryuki, et al.
Publicado: (2020)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Shimose, Shigeo, et al.
Publicado: (2023)

Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
por: Suzuki, Hiroyuki, et al.
Publicado: (2023)

Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma
por: Tsuchihashi, Jin, et al.
Publicado: (2021)

The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function
por: Iwamoto, Hideki, et al.
Publicado: (2022)

Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces “angiogenic switch off” in a hepatoma mouse model
por: Iwamoto, Hideki, et al.
Publicado: (2015)

Effects of In-Hospital Physical Therapy on Activities of Daily Living in Patients with Hepatocellular Carcinoma
por: Narao, Hayato, et al.
Publicado: (2020)

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
por: Koga, Hironori, et al.
Publicado: (2023)

Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
por: Iwamoto, Hideki, et al.
Publicado: (2021)

A low‐intensity 10‐min resistance exercise program that ameliorated hepatic fibrosis indices and altered G‐CSF/IP‐10/PDGF‐BB in a patient with nonalcoholic fatty liver disease: A case report
por: Hashida, Ryuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ao2khfp2t84hikqpqif10e773